Potential of metabolism-related drugs for treating obstructive sleep apnea and obesity

Emerging evidence indicates that **SGLT2 inhibitors, GLP-1 receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists may be beneficial for treating obesity in individuals with obstructive sleep apnea.

• SGLT2 inhibitors and GLP-1 receptor agonists may lead to weight reduction, with GLP-1 receptor agonists showing slightly better performance.
• Preliminary studies suggest these medications could improve management of obstructive sleep apnea beyond weight loss alone.
• Reductions in the apnea-hypopnea index have been observed in association with the use of these metabolic drugs.
• Potential improvements in other sleep-related outcomes were noted, though further research is needed.
• There is a recognized need for more therapeutic options for sleep apnea, as current treatments often face adherence challenges.

Simplified